Influence of storage conditions on the viability of spheroids from human chondrocytes

Abstract

BACKGROUND: The use of tissue-engineered products for treating hyaline cartilage injuries is currently a promising direction for regenerative medicine. The study of storage and transportation conditions of such preparations is essential in product development because it determines the viability and functional activity of the cellular component of the product. In addition, such work should be performed following the requirements of Russian legislation before using the developed drug product in clinical trials.

AIM: To characterize the storage conditions for tissue-engineered preparations such as chondrospheres.

METHODS: Chondrospheres were formed from human chondrocytes obtained from the biopsy material of the knee joint cartilage of patients diagnosed according to ICD-10 codes M15–M19. After the formation of chondrospheres, cell viability was examined using the metabolic dye PrestoBlue, and the expression of chondrogenic markers (SOX9, aggrecan, collagen type 1 and type 2) was preserved using real-time polymerase chain reaction under various transportation conditions, i.e., at different storage times, medium composition, and temperature.

RESULTS: The analysis of the expression of chondrocyte markers confirmed that cells in chondrospheres retain a chondrocyte phenotype. In the cell viability study of tissue-engineered products under various conditions (temperature, solution, and time), the most favorable environment for storing the product was phosphate buffer saline and 0.9% sodium chloride solution (р <0.05). The metabolic activity of the cells that make up the tissue-engineered product was maintained when stored at +4 °C for up to 3 days (р <0.05).

CONCLUSION: Isotonic solution and temperature regime +4 °C for not more than 2 days showed the preferable medium and conditions for storing and transporting the prototype cartilage implant as chondrospheres.

Keywords

tissue engineering / chondrocytes / drug storage

References

[1] Mironov SP, Omel’yanenko NP, Коп Е, et al. Classification and methods of treatment of cartilage defects. N.N. Priorov Journal of Traumatology and Orthopedics. 2008;(3):81–86. EDN: JTGGMH

[2] Миронов С.П., Омелъяненко Н.П., Кон Е., и др. Классификация и методы лечения хрящевых дефектов // Вестник травматологии и ортопедии им. Н.Н. Приорова. 2008. № 3. С. 81–86. EDN: JTGGMH

[3] Novoselov KA, Kulyaba TA, Kornilov NN, et al. Diagnosis and treatment of local damage to the cartilage of the knee joint: a manual for doctors. Saint Petersburg; 2004. (In Russ).

[4] Новоселов К.А., Куляба Т.А., Корнилов Н.Н., и др. Диагностика и лечение локальных повреждений хряща коленного сустава: пособие для врачей. Санкт-Петербург, 2004.

[5] Kerzner B, Fortier LM, Swindell HW, et al. An update on the use of orthobiologics combined with corrective osteotomies for osteoarthritis: osteotomy site and intra-articular efficacy. Operative Techniques in Sports Medicine. 2022;30(3):150933. EDN: KEHCWP doi: 10.1016/j.otsm.2022.150933

[6] Kerzner B., Fortier L.M., Swindell H.W., et al. An update on the use of orthobiologics combined with corrective osteotomies for osteoarthritis: osteotomy site and intra-articular efficacy // Operative Techniques in Sports Medicine. 2022. Vol. 30, N 3. P. 150933. EDN: KEHCWP doi: 10.1016/j.otsm.2022.150933

[7] Eremeev A, Belikova L, Ruchko E, et al. Brain organoid generation from induced pluripotent stem cells in home-made mini bioreactors. J Vis Exp. 2021;(178):e62987. doi: 10.3791/62987

[8] Eremeev A., Belikova L., Ruchko E., et al. Brain organoid generation from induced pluripotent stem cells in home-made mini bioreactors // J Vis Exp. 2021. N 178. P. e62987. doi: 10.3791/62987

[9] https://www.ema.europa.eu/ [Internet]. CHMP assessment report. Spherox Common name: spheroids of human autologous matrix-associated chondrocytes Procedure No. EMEA/H/C/002736/0000 2017 [cited: 2023 Nov 11]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/spherox-epar-public-assessment-report_en.pdf

[10] https://www.ema.europa.eu/ [Internet]. CHMP assessment report. Spherox Common name: spheroids of human autologous matrix-associated chondrocytes Procedure No. EMEA/H/C/002736/0000 2017. Режим доступа: https://www.ema.europa.eu/en/documents/assessment-report/spherox-epar-public-assessment-report_en.pdf Дата обращения: 28.11.2023.

[11] Eremeev AV, Pikina AS, Ruchko ES, et al. Fabrication of cartilage tissue substitutes from cells with induced pluripotency. Medicine of Extreme Situations. 2022;(4):31–42. EDN: WKQYHL doi: 10.47183/mes.2022.037

[12] Еремеев А.В., Пикина А.С., Ручко Е.С., и др. Получение хрящеподобных структур из стволовых клеток с индуцированной плюрипотентностью // Медицина экстремальных ситуаций. 2022. № 4. С. 31–42. EDN: WKQYHL doi: 10.47183/mes.2022.037

[13] Shajib MS, Futrega K, Franco RAG, et al. Method for manufacture and cryopreservation of cartilage microtissues. J Tissue Eng. 2023;14:20417314231176901. doi: 10.1177/20417314231176901

[14] Shajib M.S., Futrega K., Franco R.A.G., et al. Method for manufacture and cryopreservation of cartilage microtissues // J Tissue Eng. 2023. Vol. 14. P. 20417314231176901. doi: 10.1177/20417314231176901

[15] Eremeev AV, Pikina AS, Vladimirova TV, Bogomazova AN. Methods for assessing the viability of cells cultured in vitro in 2D and 3D structures // Genes & cells. 2023;18(1):5–21. EDN: XDGEIA doi: 10.23868/gc312198

[16] Еремеев А.В., Пикина А.С., Владимирова Т.В., Богомазова А.Н. Методы оценки жизнеспособности клеток, культивируемых in vitro в 2D- и 3D-структурах // Гены и Клетки. 2023. Т. 18, № 1. С. 5–21. EDN: XDGEIA doi: 10.23868/gc312198

[17] Eremeev AV, Volovikov EA, Shuvalova LD, et al. “Necessity is the mother of invention” or inexpensive, reliable, and reproducible protocol for generating organoids. Biokhimiya. 2019;84(3):448–456. EDN: YZLVEL doi: 10.1134/S032097251903014X

[18] Еремеев А.В., Воловиков Е.А., Шувалова Л.Д., и др. «Голь на выдумки хитра», или дешевый, надежный и воспроизводимый способ получения органоидов // Биохимия. 2019. Т. 84, № 3. С. 448–456. EDN: YZLVEL doi: 10.1134/S032097251903014X

[19] https://assets.thermofisher.com/ [Internet]. PrestoBlue® Cell Viability Reagent Documentation [cited: 2023 Nov 11]. Available from: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/PrestoBlueFAQ.pdf

[20] https://assets.thermofisher.com/ [Internet]. PrestoBlue® Cell Viability Reagent Documentation. Режим доступа: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/PrestoBlueFAQ.pdf Дата обращения: 27.11.2023.

[21] Bekkers JE, Saris DB, Tsuchida AI, et al. Chondrogenic potential of articular chondrocytes depends on their original location. Tissue Eng Part A. 2014;20(3-4):663–671. doi: 10.1089/ten.TEA.2012.0673

[22] Bekkers J.E., Saris D.B., Tsuchida A.I., et al. Chondrogenic potential of articular chondrocytes depends on their original location // Tissue Eng Part A. 2014. Vol. 20, N 3-4. P. 663–671. doi: 10.1089/ten.TEA.2012.0673

[23] Tchetina EV, Squires G, Poole AR. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J Rheumatol. 2005;32(5):876–886.

[24] Tchetina E.V., Squires G., Poole A.R. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions // J Rheumatol. 2005. Vol. 32, N 5. P. 876–886.

[25] Grogan SP, Miyaki S, Asahara H, et al. Mesenchymal progenitor cell markers in human articular cartilage: normal distribution and changes in osteoarthritis. Arthritis Res Ther. 2009;11(3):R85. doi: 10.1186/ar2719

[26] Grogan S.P., Miyaki S., Asahara H., et al. Mesenchymal progenitor cell markers in human articular cartilage: normal distribution and changes in osteoarthritis // Arthritis Res Ther. 2009. Vol. 11, N 3. P. R85. doi: 10.1186/ar2719

[27] Lyon RC, Taylor JS, Porter DA, et al. Stability profiles of drug products extended beyond labeled expiration dates. J Pharm Sci. 2006;95(7):1549–1560. doi: 10.1002/jps.20636

[28] Lyon R.C., Taylor J.S., Porter D.A., et al. Stability profiles of drug products extended beyond labeled expiration dates // J Pharm Sci. 2006. Vol. 95, N 7. P. 1549–1560. doi: 10.1002/jps.20636

RIGHTS & PERMISSIONS

Eco-Vector